Aspirin (Acetylsalicylic Acid) — Evidence-Based Health Benefits

Aspirin (acetylsalicylic acid, ASA) is one of the oldest and most extensively studied drugs in modern medicine. Synthesized in its stable acetylated form by Bayer chemist Felix Hoffmann in 1897, aspirin has been the subject of more than 700 randomized controlled trials and hundreds of meta-analyses. Today its uses extend well beyond pain and fever relief: low-dose aspirin is a foundational therapy for secondary cardiovascular prevention, an evidence-supported intervention for pre-eclampsia prophylaxis, a candidate chemopreventive agent for colorectal cancer, and a topic of ongoing research in dementia, diabetes, and inflammatory disease. This article reviews the major evidence-based benefits, mechanisms, and the rapidly evolving guidance about who should — and should not — take aspirin.

Introduction
Antiplatelet Effect & Cardiovascular Protection
Anti-Inflammatory Mechanism
Pain & Fever Relief
Colorectal Cancer Risk Reduction
Pre-Eclampsia Prevention in Pregnancy
Migraine & Cluster Headache
Dementia & Alzheimer's Research
Diabetes & Insulin Sensitivity Research
Dosing Forms & Pharmacology
Who Should and Should Not Take Aspirin
References & Research Papers
Connections
Featured Videos

Introduction

Aspirin's parent compound, salicin, has been used for thousands of years in the form of willow bark (Salix alba) extracts described by Hippocrates and the ancient Egyptians. The acetylated derivative produced commercially by Bayer in 1899 reduced gastric irritation and improved tolerability, launching the modern era of nonsteroidal anti-inflammatory drug (NSAID) therapy.

What makes aspirin pharmacologically unique among NSAIDs is its irreversible inhibition of cyclooxygenase (COX) enzymes via acetylation of a serine residue in the active site. In platelets — which lack a nucleus and cannot synthesize new enzyme — this means a single low dose silences thromboxane A₂ production for the entire 7–10 day platelet lifespan. This irreversible, dose-asymmetric pharmacology is the molecular basis for aspirin's distinctive role in cardiovascular medicine.

Modern clinical use of aspirin spans four broad domains: (1) acute and chronic antiplatelet therapy in cardiovascular disease, (2) symptomatic relief of pain and fever, (3) emerging chemoprevention applications, and (4) targeted obstetric use. Each domain has a distinct evidence base and risk-benefit calculus.

Antiplatelet Effect & Cardiovascular Protection

Aspirin's cardiovascular benefit derives almost entirely from its irreversible acetylation of cyclooxygenase-1 (COX-1) in platelets. COX-1 catalyzes the conversion of arachidonic acid into prostaglandin H₂, which platelet thromboxane synthase then converts into thromboxane A₂ (TXA₂) — a potent vasoconstrictor and platelet aggregator. By blocking TXA₂ production, aspirin reduces platelet aggregation and arterial thrombus formation.

Key Pharmacologic Features

Irreversible acetylation: Aspirin acetylates Ser529 of COX-1, permanently inactivating the enzyme. Because platelets cannot synthesize new protein, the antiplatelet effect persists for the platelet's 7–10 day lifespan.
Low-dose selectivity: Doses of 75–100 mg/day are sufficient to fully inhibit platelet COX-1 while largely sparing endothelial COX-2-derived prostacyclin (PGI₂), which has opposing antithrombotic and vasodilatory effects.
Steady-state achieved within days: Daily low-dose aspirin produces near-complete platelet inhibition within 5–7 days. A 162–325 mg loading dose (chewed) achieves rapid inhibition during acute myocardial infarction.

Secondary Prevention

The Antithrombotic Trialists' (ATT) Collaboration meta-analysis of 16 secondary-prevention trials (17,000 patients) showed that aspirin reduces serious vascular events by approximately 20% in patients with prior myocardial infarction, ischemic stroke, or established atherosclerotic disease. Absolute event reduction of roughly 1.5% per year clearly outweighs the bleeding risk in this population, making aspirin a foundational secondary-prevention therapy alongside statins and blood pressure control.

Acute Coronary Syndromes

In suspected acute myocardial infarction, the landmark ISIS-2 trial demonstrated that 162.5 mg of chewed aspirin reduced 5-week vascular mortality by 23% — a benefit comparable in magnitude to streptokinase thrombolysis, and additive when combined with it. Chewing rather than swallowing accelerates absorption through the buccal mucosa, achieving therapeutic plasma levels within 15–20 minutes.

Primary Prevention — A Narrowed Indication

In patients without established cardiovascular disease, the absolute benefit of aspirin is much smaller and is largely offset by an increase in major bleeding. Three large 2018 trials — ASPREE (elderly), ARRIVE (moderate risk), and ASCEND (diabetes) — all failed to show net benefit for primary prevention in their populations. The 2022 USPSTF guidance accordingly narrowed primary-prevention recommendations dramatically (see §11).

Anti-Inflammatory Mechanism

At higher doses (typically ≥1,000 mg/day in divided doses), aspirin inhibits both COX-1 and COX-2, the inducible isoform expressed at sites of inflammation. COX-2 catalyzes the production of pro-inflammatory prostaglandins — principally PGE₂ and PGI₂ — which mediate vasodilation, plasma extravasation, leukocyte recruitment, and sensitization of pain fibers.

Downstream Effects

Reduced PGE₂ synthesis: Decreases vasodilation, capillary permeability, and edema at inflammatory sites.
Suppression of nociceptor sensitization: PGE₂ lowers the firing threshold of peripheral pain neurons; reducing it raises the pain threshold (peripheral analgesia).
Hypothalamic temperature reset: Inhibition of central PGE₂ in the preoptic hypothalamus restores the body's thermal set-point during fever.
Aspirin-triggered lipoxins (ATLs): Acetylated COX-2 produces 15-epi-lipoxin A₄, an active resolution-of-inflammation lipid mediator. This may explain why aspirin has anti-inflammatory effects beyond simple prostaglandin blockade.

Clinical Anti-Inflammatory Uses

Rheumatic fever and Kawasaki disease: High-dose aspirin (80–100 mg/kg/day in divided doses) remains a standard component of acute therapy for Kawasaki disease in pediatric cardiology.
Pericarditis: High-dose aspirin (650–1,000 mg three times daily, tapered over weeks) is a first-line treatment for acute and recurrent pericarditis, often in combination with colchicine.
Historical role in inflammatory arthritis: Once a mainstay of rheumatoid arthritis management, aspirin has been largely replaced by safer NSAIDs and disease-modifying agents but remains a reference compound.

Pain & Fever Relief

Aspirin was the first widely available synthetic analgesic and antipyretic, and it remains a useful agent for mild-to-moderate pain in adults who can tolerate NSAIDs.

Analgesic Profile

Effective for: Headache, muscle aches, dysmenorrhea, dental pain, low-grade musculoskeletal pain, and post-operative pain (often as adjunct).
Onset: 30–60 minutes for plain tablets; faster (15–20 minutes) when chewed; slower for enteric-coated forms.
Standard adult analgesic dose: 325–650 mg every 4–6 hours, not to exceed 4 g/day.
Ceiling effect: As with other NSAIDs, increasing the dose above ~1,000 mg per dose does not substantially increase analgesia but does increase side effects.

Antipyretic Effect

Aspirin reliably reduces fever in adults by inhibiting hypothalamic prostaglandin E₂ synthesis. However, paracetamol (acetaminophen) and ibuprofen are now generally preferred for routine antipyresis because of better gastrointestinal tolerability and the critical contraindication in children.

Reye Syndrome — A Pediatric Contraindication

Aspirin is contraindicated in children and adolescents (under ~19 years) with viral illnesses because of its association with Reye syndrome — a rare but devastating condition of acute hepatic failure and encephalopathy. Following public health warnings beginning in the 1980s, pediatric Reye syndrome cases dropped from hundreds per year in the US to fewer than two per year. Children with febrile illness should receive paracetamol or ibuprofen, not aspirin, except in specific supervised settings such as Kawasaki disease.

Colorectal Cancer Risk Reduction

The chemopreventive effect of aspirin against colorectal cancer (CRC) is one of the strongest non-cardiovascular benefits supported by long-term randomized data. Multiple meta-analyses and pooled cohorts demonstrate that long-duration aspirin use reduces both CRC incidence and mortality.

Evidence Base

Pooled long-term RCT data (Rothwell et al., Lancet 2010 and 2011): Daily aspirin for ≥5 years reduced 20-year CRC incidence by approximately 24% and CRC mortality by 35%. The benefit emerges only after a 5- to 10-year latency.
CAPP2 trial: In carriers of Lynch syndrome (hereditary non-polyposis CRC), 600 mg/day aspirin for at least 2 years reduced CRC incidence by approximately 50% over 10-year follow-up — a particularly compelling benefit in a high-risk hereditary population.
Adenoma recurrence trials: Daily aspirin reduces recurrence of colorectal adenomas by 17–28% in patients with prior polyps.

Putative Mechanisms

COX-2 is overexpressed in 80–85% of colorectal cancers; its inhibition reduces PGE₂-mediated tumor proliferation, angiogenesis, and immune evasion.
Acetylation of platelet COX-1 reduces platelet-tumor cell interactions implicated in metastatic spread.
Activation of the AMPK pathway and induction of apoptosis in transformed colonic epithelium.
Possible modulation of the gut microbiome and reduction of pro-tumorigenic bacterial taxa.

Limits of the Evidence

The bleeding risk associated with chronic aspirin use is non-trivial, and the latency to CRC benefit is long. The 2016 USPSTF recommendation for low-dose aspirin in CRC prevention (in adults 50–59 with elevated cardiovascular risk) was retracted in the 2022 update; CRC chemoprevention is no longer a stand-alone indication for asymptomatic adults. Aspirin chemoprevention remains an active area of research and may still be appropriate in selected high-risk groups (e.g., Lynch syndrome) under specialist guidance.

Pre-Eclampsia Prevention in Pregnancy

Low-dose aspirin is one of the few pharmacologic interventions with high-quality evidence for reducing the risk of pre-eclampsia — a leading cause of maternal and perinatal morbidity worldwide.

The ASPRE Trial

The ASPRE trial (Rolnik et al., NEJM 2017) randomized 1,776 women at high risk of preterm pre-eclampsia (identified by first-trimester combined screening) to 150 mg aspirin nightly or placebo from 11–14 weeks until 36 weeks of gestation. Aspirin reduced the incidence of preterm pre-eclampsia by approximately 62% (1.6% vs 4.3%; adjusted OR 0.38). No significant increase in serious bleeding events was observed.

Mechanism

Pre-eclampsia is associated with deficient trophoblastic invasion of maternal spiral arteries, placental ischemia, and an imbalance in vasoactive prostanoids favoring TXA₂ over PGI₂. Low-dose aspirin selectively suppresses platelet TXA₂ while sparing endothelial PGI₂, restoring vascular balance and improving placental perfusion. Timing matters: initiation before 16 weeks of gestation appears critical to benefit, consistent with aspirin acting during placental development.

Current Guidance

USPSTF 2021: Recommends low-dose aspirin (81 mg/day) after 12 weeks of gestation in women at high risk of pre-eclampsia.
ACOG and SMFM: Concur with low-dose aspirin in high- and moderate-risk patients.
NICE (UK): Recommends 75–150 mg aspirin daily from 12 weeks until birth in at-risk women.

Migraine & Cluster Headache

Aspirin remains a useful, inexpensive, and widely available option for the acute treatment of migraine, supported by both systematic reviews and direct comparison trials.

Acute Migraine

Cochrane review (Kirthi et al., 2013): A single 900–1,000 mg oral dose of aspirin produced 2-hour pain freedom in roughly 24% of patients (vs 11% with placebo), and meaningful pain relief in 52% (vs 32% with placebo).
Combination with metoclopramide: Adding 10 mg metoclopramide reduces nausea and accelerates aspirin absorption, with efficacy comparable to oral sumatriptan 50 mg in head-to-head trials.
Effervescent or chewable formulations: Faster onset than standard tablets, useful given the typical migraine-associated gastric stasis.

Cluster Headache

While not first-line (oxygen and triptans dominate acute treatment), high-dose aspirin has been used for cluster headache in some protocols. Evidence is limited and largely anecdotal compared with migraine.

Migraine Prophylaxis

Low-dose aspirin (typically 81–325 mg/day) has been studied as a preventive in select populations, particularly migraine with aura where there is increased vascular thrombotic risk. Evidence remains mixed and aspirin is not a guideline-recommended first-line preventive.

Dementia & Alzheimer's Research

The hypothesis that aspirin might slow cognitive decline or prevent Alzheimer's disease (AD) is biologically plausible — based on neuroinflammation, microvascular thrombosis, and amyloid pathology — but the clinical evidence is mixed and, in the strongest randomized trials, largely negative.

Biological Rationale

Chronic neuroinflammation involving microglial COX-2 expression contributes to AD pathology.
Microvascular ischemia and silent cortical infarcts contribute to vascular and mixed dementia.
Observational cohorts have suggested 20–40% lower AD incidence in long-term NSAID users.

Randomized Trial Evidence

ASPREE-NEURO substudy (Ryan et al., Neurology 2020): In 19,114 healthy adults ≥70 years, 100 mg/day aspirin for a median 4.7 years did not reduce incident dementia, mild cognitive impairment, or rate of cognitive decline compared with placebo.
Earlier randomized trials of selective COX-2 inhibitors: Failed to slow AD progression and were complicated by cardiovascular safety concerns.
Observational discrepancy: Persistent associations seen in some cohorts likely reflect confounding by indication, healthy-user bias, or uncontrolled covariates.

Honest Bottom Line

Aspirin should not be prescribed for the prevention of dementia or Alzheimer's disease based on current evidence. Any cognitive benefit, if it exists, is likely small and is not detectable in well-designed randomized trials. This is an instructive example of how observational signals can fail to replicate under randomization.

Diabetes & Insulin Sensitivity Research

The relationship between aspirin and glucose metabolism has been explored for over a century — high-dose salicylates were noted to lower blood glucose in diabetic patients in the early 1900s — but modern data are nuanced.

Mechanistic Findings

IKKβ/NF-κB inhibition: High-dose salicylates inhibit the IκB kinase-β (IKKβ) pathway, a key driver of inflammation-induced insulin resistance in obesity.
Improved insulin sensitivity: Short-term studies of high-dose aspirin (~7 g/day) or salsalate (a non-acetylated salicylate) demonstrated reductions in fasting glucose, HbA1c, and inflammatory markers in patients with type 2 diabetes.
TINSAL-T2D trial (Goldfine et al., Annals of Internal Medicine 2010 and 2013): Salsalate 3.5 g/day for one year reduced HbA1c by ~0.4% in patients with type 2 diabetes.

Clinical Implications

The doses required for glycemic benefit (multi-gram daily) cause unacceptable bleeding and gastrointestinal toxicity for routine use.
Low-dose aspirin (75–100 mg) does not meaningfully alter glycemic control.
The ASCEND trial (NEJM 2018) showed that 100 mg/day aspirin in patients with diabetes but without cardiovascular disease reduced serious vascular events by 12% but increased major bleeding by 29%, yielding no clear net benefit.
Salsalate and related non-acetylated salicylates remain investigational as anti-inflammatory metabolic agents but are not first-line therapy for diabetes.

Dosing Forms & Pharmacology

Common Strengths

81 mg ("baby aspirin", low-dose): Standard for cardiovascular prophylaxis in the United States. Equivalent to "75 mg" in Europe.
100 mg: Common low-dose strength outside the US; clinical effects equivalent to 81 mg.
325 mg: Standard adult analgesic/antipyretic strength; also the historical cardiovascular loading dose.
500–650 mg: Higher analgesic doses; common in migraine treatment.
Multi-gram daily (divided doses): Used historically for inflammatory conditions, Kawasaki disease, and acute pericarditis.

Formulations

Plain (immediate-release) tablets: Onset 30–60 minutes; rapid systemic exposure.
Enteric-coated: Designed to dissolve in the small intestine to reduce gastric irritation. Onset is delayed (often 2–4 hours) and absorption can be variable. Critically, enteric-coated aspirin should not be used for acute coronary syndromes — use chewed plain or chewable aspirin instead.
Chewable tablets: Achieve rapid buccal absorption; recommended for suspected acute MI (162–325 mg chewed and swallowed).
Effervescent / soluble: Buffered formulations with faster onset and reduced gastric exposure; popular for migraine.
Rectal suppositories: Reserved for patients unable to take oral medication.

Pharmacokinetics

Absorption: Rapid in the stomach and proximal small intestine; peak plasma levels in 30–60 minutes for plain tablets.
Half-life: Aspirin itself has a plasma half-life of only 15–20 minutes; salicylate (its primary metabolite) has a dose-dependent half-life of 2–15 hours.
Mechanism duration: Despite the short plasma half-life, the antiplatelet effect persists for the full platelet lifespan (7–10 days) due to irreversible COX-1 acetylation.
Elimination: Renal excretion of salicylate and its conjugates; alkalinization of urine substantially accelerates clearance in overdose.

Who Should and Should Not Take Aspirin

Established Indications (Secondary Prevention & Acute Care)

Prior myocardial infarction, ischemic stroke, or transient ischemic attack (with appropriate antiplatelet selection).
Established coronary artery disease, including post-PCI and post-CABG patients (per current guidelines).
Symptomatic peripheral artery disease.
Acute coronary syndrome — immediate 162–325 mg chewed dose.
Acute ischemic stroke (after exclusion of hemorrhage and per current guidelines).
Selected mechanical and biological heart valves (per cardiology guidance).

Targeted Indications

Pre-eclampsia prophylaxis: 81–150 mg from 12–16 weeks of gestation in high-risk pregnancies.
Kawasaki disease: High-dose during acute phase, then low-dose during the convalescent phase.
Acute pericarditis: High-dose aspirin with taper, often combined with colchicine.
Lynch syndrome: Long-term aspirin reduces colorectal cancer risk; specialist-directed.

USPSTF 2022 Primary Prevention Guidance — Substantially Narrowed

The 2022 USPSTF guidance represents a significant tightening from the 2016 recommendation:

Adults 40–59 with ≥10% 10-year ASCVD risk: Initiation of low-dose aspirin should be an individualized decision (Grade C). Net benefit is small. Patients not at increased bleeding risk who place high value on potential benefit may reasonably choose to start.
Adults ≥60: Recommend against initiating low-dose aspirin for primary prevention (Grade D). Bleeding risk increases sharply with age and outweighs the small absolute reduction in cardiovascular events.
Continuation in patients already taking aspirin: Should be reassessed periodically; the 2022 guidance does not mandate discontinuation but encourages individualized review with attention to bleeding risk.

Contraindications and Cautions

Active bleeding (gastrointestinal, intracranial, or other major site).
Aspirin or NSAID hypersensitivity, including the aspirin-exacerbated respiratory disease (Samter's triad: asthma, nasal polyps, aspirin sensitivity).
Children and adolescents with viral illness — risk of Reye syndrome.
Severe hepatic or renal impairment.
Bleeding disorders (hemophilia, severe thrombocytopenia, advanced cirrhosis with coagulopathy).
Active peptic ulcer disease (relative contraindication; consider risk-benefit and PPI co-therapy).
Caution with concurrent anticoagulants: Combined antiplatelet/anticoagulant therapy substantially increases bleeding risk and requires specialist supervision.
Pre-procedural management: Discuss timing and continuation with the surgical or procedural team; many cardiology guidelines now favor continuation through most non-cardiac surgery in established CAD.

This article is for educational purposes and does not replace individualized medical advice. The decision to start, continue, or stop aspirin therapy should be made with a qualified clinician.